NAYA Biosciences Inc
NASDAQ:NAYA
NAYA Biosciences Inc
Accounts Payable
NAYA Biosciences Inc
Accounts Payable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
NAYA Biosciences Inc
NASDAQ:NAYA
|
Accounts Payable
$2.7m
|
CAGR 3-Years
72%
|
CAGR 5-Years
42%
|
CAGR 10-Years
N/A
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Accounts Payable
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Accounts Payable
$907m
|
CAGR 3-Years
5%
|
CAGR 5-Years
11%
|
CAGR 10-Years
13%
|
|
|
Stryker Corp
NYSE:SYK
|
Accounts Payable
$1.7B
|
CAGR 3-Years
14%
|
CAGR 5-Years
20%
|
CAGR 10-Years
18%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Accounts Payable
$4.2B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
5%
|
CAGR 10-Years
15%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Accounts Payable
$1.7B
|
CAGR 3-Years
141%
|
CAGR 5-Years
69%
|
CAGR 10-Years
39%
|
|
NAYA Biosciences Inc
Glance View
INVO BioScience, Inc. is a fertility company. The company is headquartered in Sarasota, Florida and currently employs 25 full-time employees. The company went IPO on 2008-11-11. The Company’s initial pipeline includes two novel Flex-NK Bispecific Antibodies. NY-303: its GPC3-targeted FLEX-NK Bispecific Antibody for Hepatocellular Carcinoma (HCC). NY-338: its CD38-targeted FLEX-NK Bispecific Antibody for Multiple Myeloma (MM) & Autoimmune Diseases. Its lead GPC3-targeting FLEX-NK bispecific antibody is entering Phase I/II clinical trials and positioned as a monotherapy option to address the unmet needs of the of hepatocellular carcinoma (HCC) patients not responding to standard of care with checkpoint inhibitors. INVOcell is its novel, FDA-cleared and CE-marked intravaginal culture (IVC) device. The company offers a viable alternative to vitro fertilization (IVF) that uses the female body for fertilization and incubation, keeping women at the center of the reproductive process.
See Also
What is NAYA Biosciences Inc's Accounts Payable?
Accounts Payable
2.7m
USD
Based on the financial report for Sep 30, 2024, NAYA Biosciences Inc's Accounts Payable amounts to 2.7m USD.
What is NAYA Biosciences Inc's Accounts Payable growth rate?
Accounts Payable CAGR 5Y
42%
Over the last year, the Accounts Payable growth was 44%. The average annual Accounts Payable growth rates for NAYA Biosciences Inc have been 72% over the past three years , 42% over the past five years .
You don't have any saved screeners yet